Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2022-03-28 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团2021年年度股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the 2021 Annual General Meeting (AGM) of 健民药业集团股份有限公司, dated April 8, 2022. It includes detailed agenda items for the AGM, such as the 2021 Board of Directors work report, Supervisory Board report, independent directors' report, financial reports, profit distribution plan, and other proposals to be voted on by shareholders. The document also contains detailed explanations of voting procedures and reports from various committees and directors related to the AGM. The content is consistent with presentations and materials shared during an AGM rather than the full annual report or other filings. The document length is substantial (15,000 characters), indicating it is not a brief announcement but the actual AGM materials. Therefore, the appropriate classification is AGM Information (AGM-R).
2022-03-28 Chinese
健民集团关于召开2021年度业绩暨现金分红说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about a scheduled investor meeting to discuss the 2021 annual performance and cash dividend distribution. It provides details about the meeting time, location, format (online interactive session), and participation instructions. It references the 2021 annual report and profit distribution plan that have already been disclosed elsewhere but does not contain actual financial data or the report itself. The document is essentially an invitation and information notice for an investor presentation event rather than the report or transcript itself. Therefore, it fits best under the category of Investor Presentation (IP). The document length is short (1645 characters), and it is not a report publication announcement or regulatory filing. Hence, the classification is Investor Presentation (IP) with high confidence.
2022-03-21 Chinese
健民集团2021年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the 2021 annual report summary of 健民药业集团股份有限公司 (Jianmin Pharmaceutical Group Co., Ltd.). It contains detailed financial data for the year 2021, including revenue, net profit, quarterly financial data, business overview, industry analysis, company operations, and shareholder information. The document length is 13,672 characters, which is substantial and contains comprehensive financial and operational information. It is not a brief announcement or a certification letter but a full report summary derived from the annual report. The presence of detailed financial metrics, business segments, and management discussion aligns with the characteristics of an Annual Report (10-K). Therefore, the document should be classified as an Annual Report (10-K). FY 2021
2022-03-17 Chinese
健民药业集团股份有限公司股东大会议事规则
Governance Information Classification · 95% confidence The document is titled as the "Rules of Procedure for the Shareholders' General Meeting" of a company. It details the procedures, powers, and regulations governing the conduct of shareholders' meetings, including annual and extraordinary general meetings. It does not contain financial statements, audit results, or earnings data. It is not a report of financial performance or management discussion but rather a governance document outlining meeting rules and shareholder rights. Therefore, it fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2022-03-17 Chinese
健民集团第九届监事会第十六次会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of the company regarding several items including the 2021 Supervisory Board work report, the 2021 Annual Report, the 2021 profit distribution plan, the 2021 financial final accounts and 2022 financial budget report, and the 2021 internal control self-evaluation report. The document states that these reports have been or will be submitted to the shareholders' meeting for approval and provides references to where the full reports can be found (e.g., stock exchange website). The document itself does not contain the full annual report or detailed financial statements but is an announcement of the resolutions and approvals related to these reports. The document length is short (1183 characters) and it mainly announces the resolutions and references the full reports elsewhere. According to the MENU VS MEAL RULE, this is an announcement of reports and resolutions, not the reports themselves. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-03-17 Chinese
健民药业集团股份有限公司内部控制审计报告（众环审字（2022）0110532）
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and the auditor's opinion on the effectiveness of internal controls over financial reporting as of December 31, 2021. The document is issued by a certified public accounting firm and contains an audit opinion on internal control effectiveness. It does not contain full financial statements or a comprehensive annual report but is a standalone audit report focused on internal control. The document length is short (1042 characters), but it is the actual audit report, not just an announcement. Therefore, it fits the category of Audit Report / Information (AR).
2022-03-17 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.